[Disclosure] SK hynix (000660) Adjusts Estimated Nasdaq DR Issuance Down to KRW 43.1T Due to Share Price Shift… Funding Aimed at Yongin & Cheongju Fabs

Source Fact: Financial Supervisory Service Electronic Disclosure System (DART) / 2026-07-06

Disclosure Type: Decision on Issuance of Depositary Receipts (Amended Disclosure)

💡 3-Second Summary

SK hynix has updated its estimated American Depositary Receipts (ADR) issuance amount for its Nasdaq listing from KRW 45.4T to KRW 43.1T to reflect recent stock price movements. All proceeds will be strictly deployed to fund infrastructure expansion, including the Yongin semiconductor cluster and Cheongju packaging fabs.

📊 1. [Key Disclosure Content & Financial Figures]

• Reason for Amendment: Content revision following updates to the U.S. SEC F-1 registration statement.
• Total DR Issuance Amount (in KRW):
  • Pre-amendment: KRW 45,453,450,000,000 ($45.4T)
  • Post-amendment: KRW 43,140,750,000,000 ($43.1T) (Adjusted strictly as a reference figure based on the lower baseline stock price)
• Issue Price per Underlying Share & DR (Reference Only):
  • Pre-amendment: KRW 2,555,000 per common share (KRW 255,500 per DR)
  • Post-amendment: KRW 2,425,000 per common share (KRW 242,500 per DR)
  • ※ Conversion ratio: 1 DR = 0.1 underlying common share.
• Maximum Issuance Limit: 17,790,000 new common shares (Unchanged).
• Purpose of Funds: KRW 43,140,750,000,000 allocated entirely to CapEx (Facility Funds).
  • (1) Construction of Phase 1 Fab at Yongin Semiconductor Cluster.
  • (2) Construction, equipment installation, and incidental costs for Cheongju P&T7 Advanced Packaging Fab.
  • (3) Acquisition of machinery, including Extreme Ultraviolet (EUV) Scanners.
• Listing Exchange: Nasdaq Global Select Market (U.S.)
• Key Tentative Dates: Nasdaq Listing Date (July 10), Subscription & Payment Date (July 14), Listing of Underlying New Shares (July 29).
• Lead Underwriters: BofA Securities, Citigroup, Goldman Sachs, J.P. Morgan

📈 2. [Expert Insight: Impact on Share Price]

• A Technical Revision with No Fundamental Valuation Change: The decrease of approximately KRW 2.3 trillion in the total issuance amount is an optical illusion rather than a scale reduction or capital withdrawal. It is purely driven by the drop in SK hynix’s baseline share price (from KRW 2,555,000 to KRW 2,425,000) used for calculation purposes. The final offering price and net proceeds will be determined through the upcoming global bookbuilding process.
• Strong Mid-to-Long-Term Structural Upside vs. Short-Term Dilution Risks: The fact that 100% of the massive capital will be injected into building HBM (High Bandwidth Memory) infrastructure and cutting-edge facilities (Yongin, Cheongju, and EUV scanners) acts as an unambiguous catalyst for securing future market leadership. However, because this relies on issuing up to 17.79 million new shares, the domestic market may face short-term overhang pressures and EPS dilution concerns leading up to the final listing.

📝 Editor’s Comment (by K-STOCK Editor)

This filing from SK hynix is a purely administrative adjustment to realign with updated U.S. SEC compliance frameworks and recent equity price shifts. While superficial glances might interpret the multi-trillion won drop in capital volume negatively, the core pillars—the maximum share ceiling (17.79 million shares) and the dedicated infrastructure target paths—remain completely intact. Securing deep liquidity directly from the U.S. capital markets via a Nasdaq listing will diversify funding avenues and solidify its stronghold in the HBM supply chain. Moving forward, the critical metrics to monitor will be the final institutional discount rate derived from bookbuilding and how effectively the market absorbs the new equity float scheduled for late July.

📢 Disclaimer & Source Information

• Source: This content has been structured and generated based on official filings submitted to the Financial Supervisory Service’s Electronic Disclosure System (DART).
• Investment Risk Notice: This brief is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice, an endorsement, or a solicitation to buy or sell any specific securities. All investment decisions and subsequent financial responsibilities rest entirely with the individual investor.
• Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.